**Sera Prognostics, Inc. Reports Fiscal Year 2025 Results**
Sera Prognostics, Inc., a women's health company focused on improving maternal and neonatal health, today announced its financial results for the fiscal year ended December 31, 2025. The company reported revenue of $81,000, a slight increase from $77,000 in the previous fiscal year. The increase in revenue is primarily attributable to sales of the PreTRM test, the company's flagship product for predicting preterm birth risk. Sera Prognostics continues to focus on expanding market adoption and securing reimbursement contracts with payers and health systems.
The company's operating expenses totaled $36.6 million in 2025, compared to $36.7 million in 2024. Research and development expenses decreased to $13.2 million from $14.7 million, primarily due to the winding down of the PRIME study. Selling and marketing expenses increased to $6.5 million from $5.8 million as the company began strategically hiring key positions in its commercial organization. General and administrative expenses increased to $16.7 million from $16.1 million, driven by increased personnel costs and consulting fees, partially offset by decreases in stock-based compensation expense and professional and legal fees. Sera Prognostics reported a net loss of $31.9 million, or $0.67 per share, compared to a net loss of $32.9 million, or $0.99 per share, in the prior year.
Key operational developments for Sera Prognostics in 2025 included the publication of the PRIME study in the Pregnancy Journal, demonstrating significant reductions in NICU admissions, neonatal morbidity and mortality, and preterm births. The company also continued to advance its product pipeline, with ongoing discovery, verification, and validation efforts for new biomarker tests and predictive analytic products. As of December 31, 2025, Sera Prognostics had 72 employees, including 71 full-time employees.
Looking ahead, Sera Prognostics plans to expand payments for the PreTRM test, broaden its pipeline with novel products for pregnancy-related conditions, and continually enhance its proprietary technology platform. The company also intends to build an evidence portfolio of clinical and economic outcomes driven by its products, engage with professional societies, and partner with employers to expand the payer mix. Sera Prognostics believes its existing cash and cash equivalents of $95.8 million as of December 31, 2025, will enable it to fund its operating expenses and capital expenditure requirements through 2028.
About SERA PROGNOSTICS, INC.
Sera Prognostics specializes in women’s health by developing blood-based biomarker tests and predictive analytics to improve pregnancy outcomes. Its core product, the PreTRM test, accurately predicts preterm birth risk, enabling proactive interventions. The company leverages proprietary proteomics, bioinformatics, and extensive biobanks to address unmet needs in maternal-fetal medicine, targeting healthcare providers, payers, and pregnant women worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.